Pharma & Biotech

One psilocybin session can reset a depressed brain for 6 months. fMRI data reveals how DMN suppression and neural reorganization outperform conventional treatments.

Ketamine went from CIA interrogation tool to club drug to FDA-approved antidepressant. The molecule stayed the same—our understanding transformed entirely.

MDMA therapy achieved 67% PTSD remission—double standard care. Yet FDA advisors voted No. Inside the collision of breakthrough science and regulatory skepticism.

Peter Thiel-backed Compass Pathways tried to patent psilocybin therapy. Scientists are fighting back in a $7B battle over nature's molecules.

Oregon legalized psilocybin therapy in 2020. By 2024, sessions cost $2,000 with 6-month waitlists. The gap between legalization and accessible healthcare.

In 1971, Nixon scheduled psychedelics as Schedule I, halting promising research. Fifty years later, we are only counting the cost of lost treatments.